---
title: "600750.SH (600750.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600750.SH/news.md"
symbol: "600750.SH"
name: "600750.SH"
parent: "https://longbridge.com/en/quote/600750.SH.md"
datetime: "2026-05-20T15:58:05.016Z"
locales:
  - [en](https://longbridge.com/en/quote/600750.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600750.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600750.SH/news.md)
---

# 600750.SH (600750.SH) — Related News

### [CRJZ exclusively responds: The steady growth in profits is attributed to optimized management levels and resource allocation efficiency](https://longbridge.com/en/news/286886792.md)
*2026-05-19T08:54:53.000Z*
> CRJZ stated at the performance briefing for the first quarter of 2026 that, despite a year-on-year revenue decline of 12

### [CRJZ's first quarter report shows a dramatic change in performance, with the stock price dropping rapidly from a record high](https://longbridge.com/en/news/286379071.md)
*2026-05-14T07:31:04.000Z*
> CRJZ's stock price quickly fell after reaching a year-high on April 24, closing at 23.71 yuan on May 12. Although net pr

### [China Resources Group, the "Five-Horse Carriage," delivers its performance report](https://longbridge.com/en/news/284862039.md)
*2026-05-01T03:01:08.000Z*
> The five listed companies under China Resources Pharmaceutical, namely CR Sanjiu, DEEJ, CRJZ, KPC, and TASLY, released t

### [CRJZ released its first-quarter performance, with a net profit attributable to the parent company of 288 million yuan, a year-on-year increase of 1.10%](https://longbridge.com/en/news/284009269.md)
*2026-04-24T13:12:04.000Z*
> CRJZ released its Q1 2026 performance, with revenue of 1.036 billion yuan, a year-on-year decrease of 12.49%; net profit

### [CHINARES PHARMA: Net profit for the first quarter was 312 million yuan, an increase of 1.71% year-on-year](https://longbridge.com/en/news/283977800.md)
*2026-04-24T10:02:00.000Z*
> CHINARES PHARMA announced a net profit of RMB 312 million for the first quarter, an increase of 1.71% year-on-year; tota

### [CHINARES PHARMA: CRJZ's net profit in the first quarter was 312 million yuan, a year-on-year increase of 1.71%](https://longbridge.com/en/news/283973790.md)
*2026-04-24T09:46:05.000Z*
> CHINARES PHARMA released the financial performance of CRJZ for the period ending March 31, 2026, with total operating re

### [Understanding the Market | CHINARES PHARMA rose nearly 8% after earnings, with annual profit attributable to shareholders increasing by 20.73% and revenue growth surpassing the industry average](https://longbridge.com/en/news/280394120.md)
*2026-03-25T01:35:04.000Z*
> CR Pharmaceutical rose nearly 8% after earnings, as of the time of writing, up 7.64%, reported at HKD 4.78, with a tradi

### [The Chinese Medicine ETF rose nearly 1%, with policies emphasizing the deepening of the inheritance and innovation of traditional Chinese medicine](https://longbridge.com/en/news/279880149.md)
*2026-03-20T03:04:10.000Z*
> The Chinese Medicine ETF rose nearly 1%, with policies emphasizing the deepening of the inheritance and innovation of tr